(NEW YORK)-- OPKO Health (NASDAQ: OPK) looks set for strong opening Monday morning as company moves forward with their own test kits for the novel coronavirus (2019-nCoV), a contagious virus that causes respiratory infection and has shown evidence of human-to-human transmission.
Through its subsidiary, BioReference Laboratories, OPK expects to receive specimens for testing this coming week, which could potentially spell a big week for OPK traders.
OPK Favored for US Approval
BioReference has an extensive network of patient service centers and a national logistic network, and has collaborated with the U.S. Centers for Disease Control and Prevention, the World Health Organization and other public health agencies to help identify and develop diagnostic tests for emerging infectious diseases. www.bioreference.com/coronavirus
For this very reason OPK looks to be favorite to have their test kits approved by regulators based on their past experience, but more importantly their national infrastructure of testing facilities across the US.
Hedge on Falling Market
Finally, markets look to continue their volatility this coming week from not only continued spread of coronavirus, but also sharp drop in oil market after collapse in OPEC meeting over the weekend.
look for even more money to flow into coronavirus related plays this week, which could really set the stage for possible sharp pre-market open for OPK Monday morning as trading week kicks off.
OPK experience record volume on Friday March 6th, and things look to even heat up more this coming trading week as investors rush in to take positions before any potential news of test kit testing, and CDC. The stock looks to have no resistance until around the $4.00 range, which is broken could send the stock up to test $6.00 on any positive news regarding their test kits.
Coronavirus Stock on Watch
Coronavirus is a developing story: Register for free Coronavirus stock alerts https://wallstreetnewscast.com/sectors/coronavirus/
About BioReference Laboratories, Inc.
BioReference provides comprehensive testing to physicians, clinics, hospitals, employers, government units, correctional institutions and medical groups. The company is in network with the five largest health plans in the United States, operates a network of 10 laboratory locations, and is backed by a medical staff of more than 160 MD, PhD and other professional level clinicians and scientists. For more information, visit www.bioreference.com
About OPKO Health
OPKO Health is a diversified healthcare company. In diagnostics, its BioReference Laboratories is one of the nation's largest full-service clinical laboratories; GeneDx is a rapidly growing genetic testing business; the 4Kscore® test is used to assess a patient's individual risk for aggressive prostate cancer following an elevated PSA and to help decide about next steps such as prostate biopsy; Claros® 1 is a point-of-care diagnostics platform with a total PSA test approved by the FDA. In our pharmaceutical pipeline, RAYALDEE is our first pharmaceutical product to be marketed. OPK88003, a once-weekly oxyntomodulin for type 2 diabetes and obesity - reported positive data from a Phase 2 clinical trial. It's among a new class of GLP-1/glucagon receptor dual agonists. OPK88004, a SARM (selective androgen receptor modulator) is currently being studied for various potential indications. The Company's most advanced product utilizing its CTP technology, a once-weekly human growth hormone for injection, successfully met its primary endpoint and key secondary endpoints in a Phase 3 study and is partnered with Pfizer. OPKO also has research, development, production and distribution facilities abroad.
This is NOT a solicitation to Buy or Sell any security, but rather is for informational purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Wall Street Newscast (“WSNC”) does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. In Compliance with SEC Rule 17B WSNC was not compensated for this media alert. WSNC, or any of its affiliates, hold no positions in securities mentioned above. These investments may involve a high degree of risk, thus investors are highly encouraged to consult with a financial adviser before any and all investments.
Safe Harbor Statements:
This website includes statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
Small and Micro cap, or ‘penny stocks’, involve a high degree of risk, and we highly encourage investors to consult with a financial adviser before making any and all investment decisions when investing in these type of securities
- Dynavax (DVAX) Receives $27M Vaccine Purchase Order from CDC - July 1, 2020
- As COVID-19 Cases Spike Look to PPE Stocks: $LAKE $APT $GTXO - June 15, 2020
- Spike in COVID Cases May Spell Risk Off for Overvalued Stocks and Markets - June 7, 2020
- Riot Blockchain (RIOT) a Hedge on Inflation as Bitcoin Rallies - May 13, 2020
- Stock Valuations Could Set Stage for Potential Bubble Burst - May 9, 2020
- Centennial Resource (CDEV) Boosts Liquidity $468M as WTI Crude Breaks Above $20 Barrel - May 4, 2020
- Companies Should Prepare IT Spending to Thrive in New Normal - April 16, 2020
- Great Elm Capital (GEC) Provides Ventilators and Respiratory Care Equipment - April 15, 2020
- FujiFilm (FUJIY) to Ramp Up Production of Avigan for Treatment of COVID19 - April 15, 2020
- GTX Corp (GTXO) Begins Selling KN95 Face Masks for Coronavirus Outbreak - April 8, 2020